Shield Launches Phase III of Ferric Iron Drug in Anemia
By Nuala Moran
Thursday, October 13, 2011
LONDON Shield Therapeutics Ltd. dosed the first patients in two Phase III studies of its lead product, ST10, for the treatment of iron deficiency anemia, just four months after closing its first round of venture funding.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.